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Abstract
Objective: To assess sleep problems (prevalence and predictors) in pediatric patients with acute
lymphoblastic leukemia (ALL) after themost intensive phase of therapy (induction).
Methods: Patients (≥2 years) treated according to the Dutch ALL-11 protocol were included.
Sleepwasmeasuredusingparent-reports and self-reports (Children’s SleepHabitsQuestionnaire;
CSHQ) and actigraphy. Parental sleep (Medical Outcome Study Sleep Scale) and distress and par-
enting problems (Distress Thermometer for Parents)were assessedwith questionnaires. Z-scores
were calculated for total CSHQ scores using age-appropriate scores of healthy Dutch children.
The prevalence of sleep problems (defined as a Z-score > 1) in patients with ALL was compared
to healthy children (chi-square tests). Actigraphic sleep estimateswere collected in healthyDutch
children (n = 86, 2-18 years) for comparison with patients (linear regression). Determinants of
parent-reported child sleep (total CSHQ Z-score) were identified with regressionmodels.
Abbreviations: ALL, acute lymphoblastic leukemia; ASHQ, Adolescent Sleep Habits Questionnaire; CSHQ, Children Sleep Habits Questionnaire; DCOG, Dutch ChildhoodOncology Group; DT-P,
Distress Thermometer for Parents; IQR, interquartile range;MOS,Medical Outcome Study Sleep Scale; PRO, patient-reported outcome; SLP-9, 9-item sleep problem index; SSR, Sleep Self
Report; TIB, total time in bed; TST, total sleep time.
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Results: Responses were collected for 124 patients (response rate 67%), comprising 123 parent-
reports, 34 self-reports, and 69 actigraphy assessments. Parents reported sleep problems in
38.0% of the patients compared to 15.2% in healthy children (P < .001). Patients reported fewer
sleep problems themselves: 12.1% compared to 15.8% in healthy children (P = .33). Total time
in bed (B (95% CI): 22.89 (9.55-36.22)) and total sleep time (B (95% CI):16.30 (1.40-31.19)), as
derived from actigraphy, were significantly longer in patients. More parent-reported child sleep
problems were predicted by parenting problems, more parental sleep problems, bedroom shar-
ing, and child’s sleepmedication use (explained variance: 27.4%).
Conclusions: Systematic monitoring of child and parental sleep and implementation of effective
interventions may be a gateway to improve quality of survival in pediatric ALL.
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1 BACKGROUND
Impaired sleep quality and quantity are associated with many adverse
psychosocial and physical health outcomes. Self- or proxy-reported
sleep disturbances are, for example, associated with impaired qual-
ity of life, altered pain perception, and fatigue,1–4 whereas insuffi-
cient sleep is associatedwith depressive symptoms, impaired cognitive
functioning, and an increased risk of metabolic syndrome.5–7 More-
over, in adults a longer sleep duration (>7.5 h) has also been related
to an increased risk of cardiovascular diseases, diabetes mellitus, and
obesity.8 The development of sleep problems during early childhood is
a risk factor for chronic sleepproblems.9 Childrenwith a chronic illness
have an increased risk of acute as well as chronic sleep problems com-
pared to their healthy peers.10 Therefore, attention to and treatment
of sleep problems in these vulnerable children is important.
Pediatric patients with cancer are prone to sleep problems due to
physical (i.e., tumor location, treatment, and toxicity) as well as psy-
chosocial factors (i.e., anxiety and fatigue).11–13 Acute lymphoblastic
leukemia (ALL) is the most common type of childhood cancer and it
requires an intensive treatment regimen of frequent chemotherapy
administrations over the course of 2-3 years.14 During maintenance
treatment, a relatively stable phase in which most children resume
their daily activities, sleep problems are common and often include
a behavioral component.4,15,16 Sleep duration is often adequate, but
nighttime awakenings are frequent and sleep onset latency (defined
as the minutes between bedtime and the first minute of sleep) is
longer.17,18 This indicates that the total minutes of sleep is sufficient
but sleep is fragmented. The fragmentation of sleep could still affect
patient and parental perceptions of sleep quality.
Some risk factors for sleep problems in childhood cancer patients
have previously been identified, such as glucocorticoid treatment,
younger age, sex, and co-sleeping.4,13,15,16,18 In young and severely ill
children, patient-reported outcomes (PROs) often depend on parental
reports. The potential influence of parental functioning and parent-
ing behaviors on these outcomes is often not taken into account.15,19
However, sleep problems are common in parents of pediatric can-
cer patients, with prevalence rates up to 71% in the hospital
setting.17,19–25 Many parents report elevated levels of distress shortly
after diagnosis and during treatment.26 Furthermore, altered parent-
ing strategies have been described.15,27
Therefore, it is important to capture all of the potential risk factors
(patient, medical, and parental factors) in one model, since such a pro-
file will help to identify families most in need of support. Sleep distur-
bances are an additional stressor to families facing childhood cancer.
Early identification of patients at risk for sleep problems in order to
begin intervening in a timely manner is therefore of the utmost impor-
tance. However, studies during the earlier, more intensive treatment
phases are scarce.28
Additionally, most previous studies employed only a single mode
of sleep assessment, while PROs and objective sleep outcomes
(such as polysomnography and actigraphy) provide complementary
information.29,30 Although polysomnography is considered the gold
standard, in an ambulant setting objective sleep outcomes are best
measured with actigraphy.31 Actigraphy provides quantitative sleep
parameters such as sleep duration, wake after sleep onset, and sleep
efficiency. The sleepestimatesobtainedwithactigraphycancontribute
to our understanding of clinical sleep disorders.31,32 PROs provide
valuable qualitative and subjective information on sleep behaviors and
consequences of impaired sleep (such as bedtime routines, sleep anxi-
ety, and daytime sleepiness) that cannot be assessed with actigraphy.
Moreover, PROs can explore environmental and behavioral dimen-
sions that could have implications for sleep.
In accordance with the literature during maintenance therapy for
ALL, we hypothesized that behavioral sleep problems (based on PROs)
would be even more common after induction therapy. Regarding acti-
graphic outcomes, we expected longer sleep times and more frag-
mented sleep, since patients are still recovering from the intensive
induction phase and normal daily routines are not yet resumed. To pro-
vide a comprehensive overview on sleep, the current study combined
PROs and actigraphy assessments and aimed to (1) assess the preva-
lence and types of parent- and self-reported sleep problems in pedi-
atric patients with ALL after the first, most intensive phase of therapy
(induction); (2) describe actigraphic sleep estimates; and (3) identify
determinants of parent-reported sleep problems.
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F IGURE 1 Timing of studymeasurement
2 METHODS
2.1 Patients and procedures
This study was part of the SLAAP [SLEEP] study (SLeep in children with
Acute lymphoblastic leukemia And their Parents), an observational,
longitudinal, multicenter study on sleep-wake rhythms, fatigue, and
quality of life in pediatric patients with ALL and their parents. Partic-
ipants in the SLAAP study were prospectively followed for 3 years and
participated in four to five assessments. Results on sleep during the
first measurement are reported here.
In the Netherlands, pediatric patients with any type of cancer
diagnosis or with a low-grade malignancy are included in the Dutch
Childhood Oncology Group (DCOG) registry. From this registry,
patients with ALL were identified. They were eligible to participate
in this study if they were (1) diagnosed with primary ALL and treated
according to the national first-line DCOG treatment protocol ALL-11,
open to patients aged 1 to 19 years, and (2) ≥2 years of age at assess-
ment, since the questionnaires used in this study were suitable for
patients aged 2 years and above. Furthermore, parents and patients
needed to master Dutch sufficiently to fill out the questionnaires.
Patients were recruited between August 2013 and July 2017 in
the following Dutch pediatric oncology centers: Emma Children’s
Hospital/Academic Medical Center and VU University Medical
Center Amsterdam, Wilhelmina’s Children’s Hospital/University
Medical Center Utrecht (until 2015), Princess Máxima Center for
pediatric oncology Utrecht (from 2015 onwards), Sophia Children’s
Hospital/Erasmus Medical Center Rotterdam, Beatrix Children’s
Hospital/University Medical Center Groningen, and Amalia Children’s
Hospital/Radboud University Medical Center Nijmegen. Parents and
patients (≥12 years) provided informed consent for participation.
The first study assessment was planned after induction, during cen-
tral nervous system directed therapy, which consisted of four 2-week
courses. Each course started with high-dose methotrexate for which
patients were hospitalized for approximately 4 days. During hospital-
ization, patients received intrathecal chemotherapy on day 1 and oral
mercaptopurine was taken continuously. About half of the patients
received a dose of PEG-asparaginase on day 2 of each course. No
glucocorticoids were given during this treatment phase. The assess-
ment (including questionnaires and actigraphy recordings) took place
at home in between two hospital admissions (Figure 1). Families were
instructed to start the assessment directly after discharge from the
hospital.
The Institutional Review Board of the Erasmus Medical Center
approved this study.
2.2 Measures
Parents provided general information through a survey. Child sleep
was assessed with valid and reliable parent-proxy (all ages) and self-
report (≥8 years) questionnaires. Objective sleep was estimated from
a7-day actigraphy assessment (all ages). Parental outcomes (sleep, dis-
tress, andparenting problems)were also assessedwith questionnaires.
Questionnaires were filled out either via paper and pencil or online
depending on parent/patient preference.
2.2.1 Sociodemographic information
The following information was provided on parental sociodemograph-
ics: parental age, sex, and highest attained educational level. Edu-
cational level was defined according to Statistics Netherlands and
dichotomized as low-middle or high educational level for analyses.33
Information on the following child variables was collected based on
parent-reports: age, sex, pre-existent sleep problems (defined as sleep
problems prior to the cancer diagnosis (yes or no)), comorbidity (≥1 or
no), pain (VAS score 0-10), sleep medication use (≥1 or no), and bed-
room sharing (yes or no). In case parents reported a comorbidity or
sleepmedication use, they were asked to indicate the diagnosis and/or
type ofmedication, without predefined answer categories. As only few
children were reported to have a comorbidity or to use sleep medica-
tion, these variables were dichotomized for analyses. Time since diag-
nosis was collected through the DCOG.
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2.2.2 Child sleep: Parent- and patient-reported outcomes
The Dutch Children Sleep Habits Questionnaire (CSHQ), Adolescent
Sleep Habits Questionnaire (ASHQ), and the Sleep Self-Report (SSR)
were used to assess child sleep.34–37 Scores of healthy Dutch chil-
dren are available.34–36,38 Only (sub)scales with an acceptable inter-
nal consistency (Cronbach’s alpha ≥0.60) in both the study popula-
tion and in healthy children are reported here. Recall period was the
last week for all child sleep questionnaires and higher scores were
indicative ofmore sleep problems.Missing itemswere imputed as item
means of the population if less than half of the items on a scale were
missing.36
The 33-item CSHQ was used to assess parent-reported sleep in
patients aged 2-12 years.36,37 A 33-item total score as well as subscale
scores were calculated. The internal consistency of the total score
and the following subscaleswas acceptable: bedtime resistance, sleep-
onset delay, night wakening (2- to 3-year old children), sleep duration
(2- to 3-year old children), sleep anxiety (2- to 3-year old children), and
daytime sleepiness (4- to 12-year old children).
The 26-item SSR was used to assess patient-reported sleep in
patients 8-12 years of age.35–37 It consists of 23-items that allow for
a total score and three additional questions providing information on
bedtime routines. The 23-item total score is reported here.
The ASHQ was developed parallel to the CSHQ and was used
for patient- and parent-reported sleep in adolescents aged 13-
18 years.34 TheASHQpatient- and parent-reported versions comprise
50-items and 54-items, respectively. The items allow for total and sub-
scale scores. The internal consistency of the total scores and the sub-
scales morning wakening (parent-report) and daytime sleepiness was
acceptable.
2.2.3 Child sleep: Actigraphic sleep estimates
Objective sleepwas estimated from an actigraphy (ActiGraphwGT3X-
BT, Pensacola, FL) assessment. An actigraph is a nonintrusive device
that quantifies sleep-wake rhythm by the occurrence and intensity
of limb movements. Patients were instructed to wear the actigraph
on their wrist for 24-h for 7 days. Actigraphy has been validated
against polysomnography. It has been proven adequate for the assess-
ment of sleep-wake patterns in infants, children, and adolescents.39,40
Participants kept a sleep log to facilitate correct interpretation of
the actigraphy data. Based on sleep logs and visual inspection of
the data, invalid data were identified and removed from further
analyses.
Actigraphy data were processed with ActiLife version 6.13.3. Sleep
outcomes were calculated using sleep log bedtime and wake time. The
following variables were obtained based on the Sadeh algorithm (def-
initions are provided in Table 1): sleep onset latency, total sleep time
(TST), sleep efficiency,wake after sleep onset, and number of nighttime
awakenings.40 Total time inbed (TIB), definedas thenumberofminutes
spent in bed based on sleep log bedtime and wake time. To reflect day-
time napping, 24-h TST and TIB were calculated. Variables were cal-
culated if valid data was available for at least five nights in order to
correct for individual differences and acquire stable sleep outcomes
TABLE 1 Definitions of actigraphic sleep estimates
Variable Definition
Sleep onset latency The number of minutes between
bedtime and the first minute scored
as sleep
Total sleep time The number of minutes scored as sleep
during the time spent in bed
Sleep efficiency The ratio between total sleep time and
time spent in bed
Wake after sleep onset The number of minutes awake after
sleep onset
Number of nighttime
awakenings
The total number of awakenings after
sleep onset
in children and adolescents.41 Actigraphic sleep estimates were also
obtained in healthy children (without sleep problems or sleep medi-
cations use) aged 2-18 years, with the same type of actigraph (Acti-
GraphwGT3X-BT). Valid actigraphy datawere available for 86 healthy
children (median age: 8.7 years [interquartile range, IQR]: [5.6-15.4],
52.3%males). Additional information on the recruitment, inclusion and
exclusion criteria, and sociodemographics of these healthy children is
provided in the Supporting Information Appendix.
2.2.4 Parental sleep
Parental sleep was assessed with the Medical Outcome Study Sleep
Scale (MOS-Sleep).42 This 12-item questionnaire allows for six sub-
scales and a 9-item sleep problem index (SLP-9). The SLP-9was used to
reflect parental sleep problems and represents symptoms consistent
with insomnia. The SLP-9 score ranges from 0 to 100 (higher scores
indicate more disturbed sleep) and was generated based on the MOS
manual’s guidelines.43
2.2.5 Parental distress and parenting problems
TheDistress Thermometer for Parents (DT-P) consists of a thermome-
ter (0-10 scale) on which parents indicate their overall distress, with
a score of ≥4 indicative of clinical distress.44 Additionally, it eval-
uates problem domains: practical, social, emotional, physical, cogni-
tive and parenting. The parenting problem domain evaluates whether
the parent-perceived problems were derived from contact with their
child, dealing with their child’s feelings, communication about (conse-
quences of) the illness, child independence, or issues with compliance
to advice/treatment andmedication administration. The thermometer
score and parenting problem domain (dichotomized as no parenting
problems versus at least one) were included as potential predictors of
parent-rated child sleep.
2.3 Statistical Analysis
2.3.1 Sociodemographics
Differences in age and sex between participants, nonparticipants, and
patients who were not invited to participate in the study were evalu-
ated withMann-WhitneyU tests and chi-square tests, respectively.
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2.3.2 Prevalence and types of parent- and
patient-reported sleep problems
CSHQ scores (parent-reported) were presented for toddlers (2-3
years) and school-aged children (4-12 years) separately. Age groups
were defined based on the normal development of sleep behaviors
during childhood and the availability of sleep scores of healthy chil-
dren. Patient scores were compared to age appropriate scores of
healthy children. Original databases of previously collected scores
of healthy children were used for analyses.34–36,38 Independent
samples T-tests or Mann-Whitney U tests were used for comparison
with healthy children. A two-sided P-value of <.05 was considered
statistically significant.
To reflect the prevalence of sleep problems, Z-scores were calcu-
lated for all sleep questionnaire total scores. For this purpose, the
questionnaire score (CSHQ/ASHQ/SSR) of each individual patient was
standardized to the distribution of scores of similarly aged healthy
Dutch children (Z-score = (Patient’s score – mean score of similarly
aged healthy children)/standard deviation [SD] of similarly aged
healthy children). Patients with a Z-score > 1 were considered to
have clinically relevant sleep problems, and of those, patients with a Z-
score>2were considered to have severe sleepproblems. Thepercent-
ages of patients with Z-scores exceeding 1 and 2 were calculated and
compared to the population of healthy childrenwith chi-square tests.
2.3.3 Actigraphic sleep estimates
Actigraphic sleep estimates were compared to healthy children using
linear regression models. Regression models were adjusted for age,
sex, and use of sleepmedication.
2.3.4 Determinants of parent-reported child sleep
Linear regression models were built to identify predictors of child
sleep (CSHQ/ASHQ totalZ-score). As therewere few self-reports, only
parent-reported scoreswere used. All child,medical, and parental vari-
ables mentioned above were tested, except for parental age and sex
(used for sample description only), and time since diagnosis (correlated
with phase of treatment).
A backward selection procedure was performed. First, univariate
regressions were performed for all variables. Second, variables with
a P-value < 0.15 were added to the multivariable model. Third, in a
stepwise approach, variables with the highest P-value were deleted
from the multivariable model until only variables with a P-value <0.10
remained. The proportion of explained variance of the final model was
determined.
IBM SPSS statistics version 22.0 was used for all analyses.
3 RESULTS
3.1 Study population
Of 276 eligible patients, 225 were invited to participate. Fifty-one
patients were not invited to participate mainly due to logistical issues
or severity of disease. Informed consentwas provided for 151 patients
(response rate 67%). The main reason for nonparticipation was the
burden of the study. Twenty-seven patients did not complete any of
the study assessments because of withdrawal of informed consent
before the first measurement, invalid data, or willingness to partici-
pate only from the secondmeasurement onwards. Finally, 124patients
completed at least one of the study measurements: parent-reports
(n = 123), self-reports (n = 34), and actigraphy assessment (n = 69)
(Figure 2). In accordance with the study design, the majority of mea-
surements took place during central nervous system directed ther-
apy (Table 2). Nevertheless, some measurements were planned during
induction ormaintenance treatment because of parent/patient prefer-
ence. For patients duringmaintenance treatment, receiving cyclic dex-
amethasone (n=14),measurementswere plannedduring aweekwith-
out dexamethasone treatment in order to limit the potential effect of
dexamethasone on sleep outcomes. Additional analyses showed that
the variability in timing of the study assessment did not significantly
influence total sleep Z-score or actigraphic sleep estimates (Table S1).
3.2 Sociodemographics
There were no significant differences in age and sex between partici-
pants (median age at diagnosis: 5.1 years, IQR: 3.1-9.2, 39.5% females)
and nonparticipants (median age at diagnosis: 5.5 years, IQR: 3.5-
11.5, 43.6% females) and patients who were not invited to partici-
pate (median age at diagnosis: 5.8 years, IQR: 3.8-11.5, 45.1% females).
Median age at diagnosis of the patients who participated in the self-
reports and actigraphy was 12.2 years (IQR: 9.4-16.0) and 5.8 years
(IQR: 3.8-9.8), respectively. Sex distribution and time since diagnosis
were similar to the total study population.
Eight patients used sleep medication at time of the study (mela-
tonin (n = 5), lorazepam (n = 1), unknown (n = 2)). Pre-existent sleep
problems were reported by parents of 19 patients and consisted of
problemswith initiating andmaintaining sleep (n=15), somnambulism
(n = 1), need of sibling in the room (n = 1), and two parents reported
less need of sleep for their child compared to other children.
3.3 Parental outcomes
The mean SLP-9 score of parents of patients with ALL was 36.4 ±
16.7 compared to 21.7 ± 13.8 in the general population. Almost half
of the parents reported at least one parenting problem. Furthermore,
themedian distress thermometer score was 6.0 (IQR: 3.0-8.0).
3.4 Prevalence and types of parent- and
patient-reported sleep problems
In toddlers (aged 2-3 years), CSHQ (sub)scale scores were higher (i.e.,
more sleep problems) compared to scores of healthy children (Table 3).
In school-agedpatients (aged4-12 years), parents reportedmoreover-
all sleep problems and more bedtime resistance compared to healthy
children. Parents reported more overall sleep problems andmore day-
time sleepiness in adolescents (aged 13-18 years) with ALL compared
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Eligible n=276
Approached n=225
Not invited (n=51):
Physician decision/patient burden n=7
Logistical issues n=18
Severe course of the disease/complications/deceased 
before introduction of the study n=11
Declined participation in any study n=8
Others/ unknown n=7
Informed consent 
n=151
No informed consent (n=74):
Burden of the study n=35
Complications/ treatment intensity n=4
Participation in other studies n=3
Parental factors n=4
Others n=5
Unknown n=23
Completed first 
measurement
n=124
Self-reports
n=34
Parent-reports
n=123
Actigraphy 
measurements
n=69
No completed measurements (n=27):
Withdrawn informed consent n =9 
Willing to participate from second measurement 
onwards/invalid data n=18
F IGURE 2 Patient enrollment
to healthy adolescents. Self-reports (SSR and ASHQ scores) were not
different from scores of healthy children.
In patients (2-18 years), the prevalence of parent-reported clini-
cally relevant sleep problemswas 38.0% (Z-score>1) and severe sleep
problems were reported in 16.7% (Z-score > 2), compared to 15.2%
and 4.3%, respectively, in healthy children (P< .001). The self-reported
prevalence of clinically relevant sleep problems was 12.1% compared
to 15.8% in healthy children (P = .33). None of the patients self-
reported severe sleep problems, compared to 4.3% in healthy children.
3.5 Actigraphic sleep estimates
Patients spent significantly moreminutes in bed and slept significantly
more minutes during the night (nighttime TST: B:15.27, P = 0.001,
nighttime TIB: B:22.89, P = 0.046) as well as during 24-h (24-h TST:
B:26.10, P < 0.001, 24-h TIB: B:39.04, P < 0.001) compared to healthy
children (Table 4). There were no differences in other actigraphic sleep
estimates.
3.6 Determinants of parent-reported child sleep
Results of the univariate analyses are shown in Table 5. Bedroom shar-
ing, parental sleep problems, parenting problems, and current child
sleep medication use predicted parent-reported child sleep problems
in the final multivariable model (explained variance: 27.4%) (Table 5).
4 DISCUSSION
This study assessed sleep in pediatric patients with ALL in the first
period after diagnosis combining both PROs and actigraphy assess-
ments. There was a high parent-perceived burden of sleep problems
and these were predicted by parental sleep, parenting problems, bed-
room sharing, and child’s sleep medication use. Patients did not report
an increased prevalence of sleep problems themselves. Furthermore,
except for longer sleep times, actigraphic sleep estimates were not dif-
ferent from sleep estimates in healthy children.
Parents reported a wide range of sleep difficulties in patients
with ALL instead of problems indicative of a specific sleep disorder.
Parents may perceive general sleep problems that do not meet
all criteria for a specific clinical sleep disorder (such as insomnia,
sleep-related breathing disorders, or hypersomnolence) according to
the International Classification of Sleep Disorders.45 However, the
high prevalence of clinically relevant sleep problems is still a reflec-
tion of the overall burden of sleep difficulties during this treatment
phase.
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TABLE 2 Baseline characteristics
Study
participants
(n= 124)
Child andmedical factors
Child age at diagnosis in years, median [IQR] 5.1 [3.1-9.2]
Female child sex, N (%) 49 (39.5)
Time since diagnosis in months, median [IQR] 4.5 [4.1-5.1]
Phase of treatment, N (%)
– Induction
– Central nervous system directed
therapya/high risk courses (n= 1)
– Maintenance
10 (8.1)
100 (80.6)
14 (11.3)
Preexisting sleep problems, N (%) 19 (15.3)
Use of sleepmedication, N (%) 8 (6.5)
Comorbidity, N (%)b 8 (6.5)
Bedroom sharing, N (%) 26 (21.0)
Pain VAS score, median [IQR] 3.0 [0.0-6.0]
Parental factors (n= 123)
Parental age, median [IQR] 37.0 [34.0-43.0]
Female parental sex, N (%) 97 (78.9)
Educational level, N (%)c
– Low
– Middle
– High
5 (4.1)
36 (29.3)
82 (66.7)
Parental sleep score (SLP-9)d
(n= 120), mean (SD)
36.4 (16.7)
Parental distress thermometer scoree
(n= 107), median [IQR]
6.0 [3.0-8.0]
≥1 Parenting problem (n= 119), N (%) 56 (47.1)
Abbreviations: IQR, interquartile range; SLP-9, 9-item sleep problem index.
aAlso referred to as ProtocolM.
bDown syndrome (n = 3), autism (n = 1), hypermobility (n = 1), coeliac dis-
ease (n = 1), anorectal malformation (n = 1), and cavernomas in the brain
(n= 1).
cLow = no education, primary school, lower secondary education; mid-
dle = upper secondary education, preuniversity education, intermediate
vocational education; high= higher vocational education, university.
dHigher score indicates more sleep problems.
eHigher score indicatesmore distress.
The disagreement between parent- and self-reports is consistent
with literature.34,46 A “repressive adaptive style” (a coping style includ-
ing defensiveness and minimization) has previously been described as
a possible factor of bias in self-reports of pediatric cancer patients.47
Furthermore, patientsmay change their judgment of symptoms during
cancer treatment (also referred to as “response shift”).34,48 Parental
coping can also contribute to this disagreement. Parents of pediatric
cancer patients are known to be more concerned about their child’s
health and social adjustment.27 This could lead to an overreporting of
problems.
The longer actigraphic sleep times are probably favorable for
physical recovery in this treatment phase and may result from
cancer-related fatigue, a common side-effect of cancer treatment.49
However, more sedentary behavior has been associated with adverse
health outcomes, such as a higher cardiovascular risk and an unfavor-
able body composition.50 In adult cancer patients, sedentary behav-
ior has also been associated with an increased risk of cancer-specific
mortality.51 Therefore, monitoring time in bed and encouraging appro-
priate degrees of physical activity as early as possible is important and
has shown to be feasible in pediatric patients with ALL.52
The parent-reported problemswith initiating andmaintaining sleep
in toddlers were not detected with actigraphy. This may have sev-
eral explanations. First, actigraphy may be less accurate in patients
with sleep problems than in good sleepers.40 Moreover, subjective
and objective sleep quality can strongly differ. Second, parents of
patients with ALL employ more sleep managing strategies (such as co-
sleeping, providing food in the bedroom, and comforting activities).15
Our results may indicate that these strategies are successful, but
require substantial efforts from parents. Third, the high prevalence
of parent-reported sleep problems may reflect impaired parental psy-
chosocial functioning. Parental distress levels were high and signif-
icantly associated with parent-reported child sleep in the univari-
ate analysis. Parental distress was not retained in the multivari-
able model, but this is most likely the result of the high correla-
tion between parental sleep and distress, which has been previously
described.21
Parent-reported sleep problems were mainly predicted by parental
sleep and parenting factors in our model. The correlation between
parental and child sleep has previously been described during ALL
maintenance treatment.19 This relationship is probably bidirectional.
Child sleep can interfere with parental sleep, whichmay in turn impact
both parenting strategies as well as parents’ perception of their child’s
sleep. Child sleep improves with consistent bedtime routines.53 To
achieve this, parents need to be consistent, engage in limit setting, and
teach their children healthy sleep behaviors. This is a challenge for par-
ents with poor sleep as they might, for example, feel more fatigued.
It is therefore important to address both child and parental sleep.
Also, it can be challenging for parents of pediatric cancer patients
to reinforce rules, since they tend to be more lenient toward their
children.15,27
Parents’ knowledge on healthy child sleep is generally poor andmay
contribute to parenting problems regarding sleep.54 An educational
intervention to improve sleep knowledge in parents of healthy chil-
dren has proven to be effective.55 Implementing interventions incor-
porating psycho-education and parenting support may prevent devel-
opment of chronic sleep problems in pediatric patients with ALL.
Since the determinants in our model explained 27.4% of the vari-
ance, future research is needed to identify additional predictors of
parent-reported sleep problems in pediatric ALL.
This study has some limitations. First, not all patients participated in
all study elements (parent-reports, self-reports, and actigraphy). Par-
ticipation bias, for example, based on treatment toxicity, cannot be
excluded. Second, because of the small sample of self-reports, these
results should be interpreted with caution. Third, parenting strategies
and preexisting parenting problems were not evaluated in this study,
although this would have provided information on the psychosocial
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TABLE 3 Descriptive statistics of parent- and patient-reported sleep outcomes and comparison between patients with ALL and healthy
children
Patients with ALL Healthy children P-value
Mean (SD)/median [IQR] Mean (SD)/median [IQR]
Parent-reports
CSHQ 2–3 years (n= 42)a
Total score 48.91 (7.75) 41.89 (5.56) <.001
Bedtime resistance 7.09 [6.31-11.00] 6.00 [6.00-7.50] <.001
Sleep duration 3.00 [3.00-5.00] 3.00 [3.00-4.00] .006
Sleep Anxiety 5.63 [4.00-7.00] 5.00 [4.00-6.00] .001
Night wakening 6.00 [4.00-7.00] 4.00 [3.00-5.00] <.001
Sleep onset delay 1.00 [1.00-2.00] 1.00 [1.00-1.00] .010
CSHQ 4–12 years (n= 61)a
Total score 44.02 (5.99) 40.44 (5.40) <.001
Bedtime resistance 7.00 [6.00-8.00] 6.00 [6.00-7.00] <.001
Daytime sleepiness 11.00 [9.06-13.00] 11.00 [9.00-13.00] .234
Sleep onset delay 1.00 [1.00-1.00] 1.00 [1.00-1.00] .984
ASHQ 13–18 (n= 20)a
Total score 34.58 (9.23) 29.23 (9.72) .022
Morning wakening 7.08 [6.00-11.75] 8.00 [5.49-10.00] .897
Daytime sleepiness 3.00 [2.00-5.00] 2.00 [1.00-3.71] .024
Self-reports
SSR 8-12 years (n= 17)a
Total score 32.59 (4.82) 31.61 (5.31) .455
ASHQ 13-18 years (n= 16)a
Total score 39.43 (10.18) 41.87 (10.52) .361
Daytime sleepiness 12.00 [9.50-14.75] 12.00 [10.00-14.00] .832
Abbreviations: ALL, acute lymphoblastic leukemia; ASHQ, Adolescent Sleep Habits Questionnaire; CSHQ, Children Sleep Habits Questionnaire; IQR,
interquartile range; SSR, sleep self-report.
Significant P-values are bold.
aHigher scores indicatemore sleep problems.
TABLE 4 Descriptive statistics of actigraphic sleep estimates and linear regressionmodels for comparison between patients with ALL and
healthy children
Patients with ALL (n= 69) Healthy children (n= 86) B (95%CI)a P-value
Mean (SD)/median [IQR] Mean (SD)/median [IQR]
Nighttime sleep
Sleep onset latency (minutes) 22.86 [16.43-38.04] 20.29 [12.25-30.79] 1.68 (–3.73; 7.09) .541
Sleep efficiency (%) 76.56 (7.71) 78.30 (6.86) –0.55 (–2.83; 1.73) .633
Total time in bed (minutes) 663.64 (46.60) 646.07 [569.00-667.59] 22.89 (9.55; 36.22) .001
Total sleep time (minutes) 506.76 (52.84) 482.24 (51.39) 15.27 (0.31; 30.22) .046
Wake after sleep onset (minutes) 128.96 (46.98) 113.31 (42.64) 6.37 (–7.14; 19.88) .353
Number of nighttime awakenings (N) 29.19 (6.70) 28.35 (6.63) 0.14 (–2.03; 2.30) .902
24-Hour sleep
Total time in bed (minutes) 687.85 (64.67) 623.88 (78.36) 39.04 (23.53; 54.54) <.001
Total sleep time (minutes) 523.83 (55.88) 486.71 (53.96) 26.10 (11.72; 40.48) <.001
Abbreviation: IQR, interquartile range.
Significant P-values are bold.
aModels adjusted for age, sex, and current sleepmedication use.
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TABLE 5 Univariate regressionmodels for associations with overall parent reported child sleep (total sleep questionnaire scores) and final
multivariable model
Univariate analyses Final multivariablemodel
Total sleep score
B (95%CI) P-value
Total sleep score
B (95%CI)
Standardized
beta P-value
Child andmedical factors
Child age at assessment –0.06 (–0.10; –0.01) .025 – – –
Female child sex 0.13 (–0.34; 0.60) .584 – – –
Phase of treatmenta: – – –
- Induction
- Maintenance
0.51 (–0.43; 1.45)
0.17 (–0.60; 0.93)
.287
.670
Pre-existent sleep problems 0.64 (0.01; 1.26) .047 – – –
Sleepmedication use 0.84 (–0.25; 1.94) .131 0.97 (0.11; 1.82) 0.19 .027
Comorbidity 1.22 (0.31; 2.13) .009 – – –
Pain VAS score 0.09 (0.02; 0.17) .011 – – –
Parental and parenting factors
Higher educational level –0.06 (–0.56; 0.45) .831 – – –
Bedroom sharing 0.90 (0.38; 1.42) .001 0.90 (0.46; 1.34) 0.35 <.001
Parental distress 0.10 (0.02; 0.19) .013 – – –
Parenting problems 0.69 (0.28; 1.10) .001 0.02 (0.01; 0.03) 0.26 .004
Parental sleep problems 0.02 (0.01; 0.04) <.001 0.51 (0.13; 0.89) 0.23 .009
aCentral nervous system directed therapy (protocolM) was used as a reference category.
CI: confidence interval P-values< 0.15 (cut-off value for multivariable regressionmodel) are bold.
risk of families. Finally, a lower socioeconomic status has been asso-
ciated with less healthy sleep behaviors; the overrepresentation of
highly educated families in our study may therefore have underesti-
mated sleep disturbances.33,56
In conclusion, parent-reported sleep problems are common after
induction therapy and parental sleep and parenting factors are the
most important predictors in our model. Parents should therefore be
supported in parenting and coping with their child’s sleep behaviors.
Furthermore, systematic attention to both child and parental sleep by
clinicians is of major importance. Given the adverse outcomes associ-
ated with impaired sleep, systematic sleep monitoring and developing
effective interventionsmaybeagateway to improvequalityof survival.
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